Create a free Feed Strategy account to continue reading

EU group: Reduce colistin sales by 65 percent

With the aim to decrease the risk of antibiotic resistance, sales of the antibiotic colistin should be cut by 65 percent, according to a new report from the Antimicrobial Advice Ad Hoc Expert Group of the European Medicines Agency.

antibiotics-eraser
Dmytro Kozak | Bigstock.com

With the aim to decrease the risk of antibiotic resistance, sales of the antibiotic colistin should be cut by 65 percent, according to a new report from the Antimicrobial Advice Ad Hoc Expert Group (AMEG) of the European Medicines Agency (EMA).

In the future, colistin-containing medicines should only be used as a second-line treatment in animals, and their sales should be minimized across all European Union (EU) Member States, EMA recommends. The advice updates the agency’s guidance from 2013, taking into account the views of stakeholders during a public consultation.

These actions follow the discovery of a new mechanism used by bacteria to develop resistance. This involved a gene – known as the mcr-1 gene – which is easily transferred between different bacterial species. First identified in southern China, the gene has since been discovered in Europe and other regions of the world.